Type 2 diabetes: Novel SGLT2 inhibitor enavogliflozin shows superior glycemic efficacy over dapagliflozin
India: A recent meta-analysis published in Diabetes & Metabolic Syndrome: Clinical Research & Reviews has shown the superiority of enavogliflozin over dapagliflozin for type 2 diabetes mellitus (T2DM) concerning certain clinical aspects over 6 months of clinical use.
Enavogliflozin was found to be a well-tolerated and effective sodium glucose co-transporter-2 inhibitor (SGLT2i). Over 24 weeks of treatment, enavogliflozin had superior glycemic efficacy and adverse events similar to dapagliflozin.
Enavogliflozin is a novel SGLT2 inhibitor developed in South Korea. Deep Dutta, Department of Endocrinology, Center for Endocrinology Diabetes Arthritis & Rheumatism (CEDAR) Superspeciality Healthcare, Dwarka, New Delhi, India, and colleagues conducted the meta-analysis to analyze the safety and efficacy of enavogliflozin in type 2 diabetes.
For this purpose, the researchers systematically searched the electronic databases for randomized controlled trials (RCTs) involving patients with type 2 diabetes receiving enavogliflozin in treatment-arm, and placebo/any other medicine in control-arm.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.